Beam Therapeutics: Buy Rating Backed by BEAM-302 Progress, 2026 Data Catalyst, and De-Risked Accelerated Approval Path

William Blair analyst Sami Corwin has maintained their bullish stance on BEAM stock, giving a Buy rating on January 21.

Sami Corwin has given his Buy rating due to a combination of factors related to Beam Therapeutics’ lead program, BEAM-302, and its regulatory outlook. He highlights the significance of the upcoming fireside chat with CEO John Evans, which will provide deeper insight into the company’s progress in alpha-1 antitrypsin deficiency and allow investors to better assess the therapeutic and commercial potential of BEAM-302. Corwin also views the existing clinical data as an important foundation that supports continued confidence in the program’s trajectory.

In addition, Corwin underscores that investors should focus on the anticipated clinical data update in early 2026, which represents a key value-inflecting catalyst for the stock. He points to the company’s recent alignment with the FDA on a potential accelerated approval route based on 12‑month biomarker data as a particularly meaningful de-risking event, suggesting a clearer and potentially faster regulatory path. Together, these elements—maturing clinical evidence, defined upcoming milestones, and a supportive regulatory stance—underpin his constructive view on Beam Therapeutics and support his Buy recommendation.

In another report released on January 21, J.P. Morgan also maintained a Buy rating on the stock with a $46.00 price target.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BEAM in relation to earlier this year.